JP5330381B2 - 酸化還元電位（ｏｒｐ）を測定及び使用する方法 - Google Patents
酸化還元電位（ｏｒｐ）を測定及び使用する方法 Download PDFInfo
- Publication number
- JP5330381B2 JP5330381B2 JP2010509472A JP2010509472A JP5330381B2 JP 5330381 B2 JP5330381 B2 JP 5330381B2 JP 2010509472 A JP2010509472 A JP 2010509472A JP 2010509472 A JP2010509472 A JP 2010509472A JP 5330381 B2 JP5330381 B2 JP 5330381B2
- Authority
- JP
- Japan
- Prior art keywords
- orp
- patient
- patients
- plasma
- body fluid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 58
- 210000001124 body fluid Anatomy 0.000 claims abstract description 49
- 239000010839 body fluid Substances 0.000 claims abstract description 40
- 208000014674 injury Diseases 0.000 claims abstract description 36
- 230000008733 trauma Effects 0.000 claims abstract description 25
- 206010019196 Head injury Diseases 0.000 claims abstract description 11
- 210000002381 plasma Anatomy 0.000 claims description 55
- 238000011282 treatment Methods 0.000 claims description 46
- 238000005259 measurement Methods 0.000 claims description 27
- 210000004369 blood Anatomy 0.000 claims description 20
- 239000008280 blood Substances 0.000 claims description 20
- 208000024891 symptom Diseases 0.000 claims description 19
- 230000003247 decreasing effect Effects 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 3
- 238000012544 monitoring process Methods 0.000 abstract description 39
- 239000010836 blood and blood product Substances 0.000 abstract description 30
- 229940125691 blood product Drugs 0.000 abstract description 30
- 208000010125 myocardial infarction Diseases 0.000 abstract description 27
- 230000001590 oxidative effect Effects 0.000 abstract description 15
- 208000028399 Critical Illness Diseases 0.000 abstract description 9
- 238000003745 diagnosis Methods 0.000 abstract description 7
- 230000033116 oxidation-reduction process Effects 0.000 abstract description 4
- 208000036142 Viral infection Diseases 0.000 abstract description 3
- 230000009385 viral infection Effects 0.000 abstract description 3
- 238000011156 evaluation Methods 0.000 abstract description 2
- 230000036542 oxidative stress Effects 0.000 description 45
- 210000001519 tissue Anatomy 0.000 description 29
- 201000010099 disease Diseases 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 230000000694 effects Effects 0.000 description 15
- 230000003647 oxidation Effects 0.000 description 15
- 238000007254 oxidation reaction Methods 0.000 description 15
- 238000012360 testing method Methods 0.000 description 11
- 241000700605 Viruses Species 0.000 description 10
- 238000011256 aggressive treatment Methods 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 239000003963 antioxidant agent Substances 0.000 description 9
- 230000006378 damage Effects 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000003642 reactive oxygen metabolite Substances 0.000 description 8
- 241000220010 Rhode Species 0.000 description 7
- 208000007587 Transfusion-Related Acute Lung Injury Diseases 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 7
- 239000007800 oxidant agent Substances 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 6
- 229910021607 Silver chloride Inorganic materials 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical group [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 108010017384 Blood Proteins Proteins 0.000 description 5
- 102000004506 Blood Proteins Human genes 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 102000006996 Aryldialkylphosphatase Human genes 0.000 description 4
- 108010008184 Aryldialkylphosphatase Proteins 0.000 description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 230000003244 pro-oxidative effect Effects 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 230000008736 traumatic injury Effects 0.000 description 4
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 3
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 3
- 206010008479 Chest Pain Diseases 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 108010071690 Prealbumin Proteins 0.000 description 3
- 102000009190 Transthyretin Human genes 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000009533 lab test Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- UQBOJOOOTLPNST-UHFFFAOYSA-N Dehydroalanine Chemical compound NC(=C)C(O)=O UQBOJOOOTLPNST-UHFFFAOYSA-N 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000034486 Multi-organ failure Diseases 0.000 description 2
- 208000010718 Multiple Organ Failure Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 description 2
- 230000006851 antioxidant defense Effects 0.000 description 2
- 102000028848 arylesterase Human genes 0.000 description 2
- 108010009043 arylesterase Proteins 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 208000035824 paresthesia Diseases 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- -1 superoxide ions Chemical class 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000009529 traumatic brain injury Effects 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108030002440 Catalase peroxidases Proteins 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 102100027685 Hemoglobin subunit alpha Human genes 0.000 description 1
- 108091005902 Hemoglobin subunit alpha Proteins 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101100366137 Mesembryanthemum crystallinum SODCC.1 gene Proteins 0.000 description 1
- 208000004221 Multiple Trauma Diseases 0.000 description 1
- 208000006670 Multiple fractures Diseases 0.000 description 1
- 102100030856 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 208000009893 Nonpenetrating Wounds Diseases 0.000 description 1
- 101100096142 Panax ginseng SODCC gene Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 102000013394 Troponin I Human genes 0.000 description 1
- 108010065729 Troponin I Proteins 0.000 description 1
- 102000004987 Troponin T Human genes 0.000 description 1
- 108090001108 Troponin T Proteins 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 238000001425 electrospray ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 229940124645 emergency medicine Drugs 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000004023 fresh frozen plasma Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000010871 livestock manure Substances 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940021317 other blood product in atc Drugs 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- BDJXVNRFAQSMAA-UHFFFAOYSA-N quinhydrone Chemical class OC1=CC=C(O)C=C1.O=C1C=CC(=O)C=C1 BDJXVNRFAQSMAA-UHFFFAOYSA-N 0.000 description 1
- 239000007845 reactive nitrogen species Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 101150017120 sod gene Proteins 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229910001428 transition metal ion Inorganic materials 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Electrochemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93892507P | 2007-05-18 | 2007-05-18 | |
| US60/938,925 | 2007-05-18 | ||
| PCT/US2008/063855 WO2008144481A1 (en) | 2007-05-18 | 2008-05-16 | Measurement and uses of oxidative status |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013118787A Division JP2013178277A (ja) | 2007-05-18 | 2013-06-05 | 酸化状態の測定及び使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010528290A JP2010528290A (ja) | 2010-08-19 |
| JP5330381B2 true JP5330381B2 (ja) | 2013-10-30 |
Family
ID=40122150
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010509472A Expired - Fee Related JP5330381B2 (ja) | 2007-05-18 | 2008-05-16 | 酸化還元電位（ｏｒｐ）を測定及び使用する方法 |
| JP2013118787A Pending JP2013178277A (ja) | 2007-05-18 | 2013-06-05 | 酸化状態の測定及び使用方法 |
| JP2014036847A Pending JP2014134545A (ja) | 2007-05-18 | 2014-02-27 | 酸化状態の測定及び使用方法 |
| JP2016053891A Pending JP2016118568A (ja) | 2007-05-18 | 2016-03-17 | 酸化状態の測定及び使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013118787A Pending JP2013178277A (ja) | 2007-05-18 | 2013-06-05 | 酸化状態の測定及び使用方法 |
| JP2014036847A Pending JP2014134545A (ja) | 2007-05-18 | 2014-02-27 | 酸化状態の測定及び使用方法 |
| JP2016053891A Pending JP2016118568A (ja) | 2007-05-18 | 2016-03-17 | 酸化状態の測定及び使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9063070B2 (enExample) |
| EP (1) | EP2147303B1 (enExample) |
| JP (4) | JP5330381B2 (enExample) |
| CA (2) | CA2684144C (enExample) |
| ES (1) | ES2627188T3 (enExample) |
| WO (1) | WO2008144481A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5330381B2 (ja) | 2007-05-18 | 2013-10-30 | インスティチュート フォー モレキュラー メディスン インコーポレイテッド | 酸化還元電位（ｏｒｐ）を測定及び使用する方法 |
| US8709709B2 (en) | 2007-05-18 | 2014-04-29 | Luoxis Diagnostics, Inc. | Measurement and uses of oxidative status |
| CA2817163C (en) | 2011-02-28 | 2015-02-17 | Luoxis Diagnostics, Inc. | Method and apparatus for measuring oxidation-reduction potential |
| RU2497107C2 (ru) * | 2012-01-24 | 2013-10-27 | Общество с ограниченной ответственностью "БИНАКОР-ХТ" | Способ измерения редокс потенциала биологических сред |
| AU2013249126B2 (en) | 2012-04-19 | 2015-10-01 | Aytu Bioscience, Inc. | Multiple layer gel |
| AU2013334616A1 (en) * | 2012-10-23 | 2014-06-26 | Aytu Bioscience, Inc. | Methods and systems for measuring and using the oxidation-reduction potential of a biological sample |
| JP6142122B2 (ja) * | 2013-07-31 | 2017-06-07 | 慶孝 大友 | 唾液成分のｏｒｐ数値化判定測定装置の活用方法 |
| RU2560705C2 (ru) * | 2013-11-01 | 2015-08-20 | Государственное бюджетное учреждение здравоохранения города Москвы Научно-исследовательский институт скорой помощи имени Н.В. Склифосовского Департамента здравоохранения г. Москвы | Способ мониторинга состояния пациента после трансплантации органа |
| CN107534825B (zh) * | 2015-04-22 | 2019-12-24 | 华为技术有限公司 | 音频信号处理装置和方法 |
| JP6251878B1 (ja) * | 2016-11-18 | 2017-12-27 | オルプ株式会社 | 酸化還元電位（ｏｒｐ）測定装置および利用方法 |
| JP6253171B1 (ja) * | 2017-07-25 | 2017-12-27 | 慶孝 大友 | Ｏｒｐ数値化判定装置および使用方法 |
| JP6454836B1 (ja) * | 2018-07-19 | 2019-01-16 | 慶孝 大友 | 唾液ｏｒｐ測定装置及び使用方法 |
| WO2024074617A1 (en) * | 2022-10-06 | 2024-04-11 | Institut National de la Santé et de la Recherche Médicale | Methods of diagnosing acute circulatory failure |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3956094A (en) * | 1974-03-29 | 1976-05-11 | Olin Corporation | Apparatus for monitoring available chlorine in swimming pools |
| US4225410A (en) * | 1978-12-04 | 1980-09-30 | Technicon Instruments Corporation | Integrated array of electrochemical sensors |
| US4299919A (en) * | 1980-06-30 | 1981-11-10 | St. Louis University | Perfusate redox potential controller |
| DE3278334D1 (en) * | 1981-10-23 | 1988-05-19 | Genetics Int Inc | Sensor for components of a liquid mixture |
| US4571292A (en) * | 1982-08-12 | 1986-02-18 | Case Western Reserve University | Apparatus for electrochemical measurements |
| US5682884A (en) * | 1983-05-05 | 1997-11-04 | Medisense, Inc. | Strip electrode with screen printing |
| US5260321A (en) * | 1984-11-12 | 1993-11-09 | Sandoz Ltd. | Use of 1,4-dihydropyridine derivatives and combinations thereof with calcitonins |
| US4963245A (en) * | 1986-05-02 | 1990-10-16 | Ciba Corning Diagnostics Corp. | Unitary multiple electrode sensor |
| US4865717A (en) * | 1987-05-26 | 1989-09-12 | Transducer Research, Inc. | Electrochemical micro sensor |
| US5273639A (en) * | 1988-03-31 | 1993-12-28 | Agency Of Industrial Science & Technology | Probe electrode |
| JPH0752170B2 (ja) * | 1988-05-27 | 1995-06-05 | ダイキン工業株式会社 | 拡散制限膜保持具収容容器 |
| US5312590A (en) * | 1989-04-24 | 1994-05-17 | National University Of Singapore | Amperometric sensor for single and multicomponent analysis |
| JP2506312Y2 (ja) * | 1989-10-31 | 1996-08-07 | 豊田合成株式会社 | エレクトロクロミック素子 |
| CH681351A5 (enExample) * | 1990-04-12 | 1993-03-15 | Hans Baer Dr | |
| GB2245062B (en) * | 1990-06-12 | 1994-03-16 | Nat Res Dev | Antioxidant assay |
| US5165406A (en) * | 1990-09-13 | 1992-11-24 | Via Medical Corporation | Electrochemical sensor apparatus and method |
| US5227307A (en) * | 1991-07-26 | 1993-07-13 | Diagnostic Markers, Inc. | Test for the rapid evaluation of ischemic state |
| US5387329A (en) * | 1993-04-09 | 1995-02-07 | Ciba Corning Diagnostics Corp. | Extended use planar sensors |
| NZ266640A (en) | 1993-04-30 | 1998-01-26 | Pacific Northwest Research Fou | Diagnosing genotoxic or carcinogenic status by analysing cellular redox potential where increased risk is indicated when the potential favours oxidatively derived modified nucleotides |
| GB9325189D0 (en) * | 1993-12-08 | 1994-02-09 | Unilever Plc | Methods and apparatus for electrochemical measurements |
| DE4404130A1 (de) * | 1994-02-09 | 1995-08-10 | Siemens Ag | Elektrochemische Bestimmung der Sauerstoffkonzentration |
| ES2119416T3 (es) * | 1994-03-30 | 1998-10-01 | Pacesetter Ab | Dispositivo de medida del caudal sanguineo. |
| US5672811A (en) * | 1994-04-21 | 1997-09-30 | Ngk Insulators, Ltd. | Method of measuring a gas component and sensing device for measuring the gas component |
| US5494562A (en) * | 1994-06-27 | 1996-02-27 | Ciba Corning Diagnostics Corp. | Electrochemical sensors |
| US5782879A (en) * | 1995-06-02 | 1998-07-21 | Sulzer Intermedics Inc. | Apparatus and method for discriminating flow of blood in a cardiovascular system |
| SE9504233D0 (sv) * | 1995-11-27 | 1995-11-27 | Pacesetter Ab | Implantable medical device |
| US5679532A (en) * | 1995-12-13 | 1997-10-21 | University Technology Corporation | Serum ferritin as a predictor of the acute respiratory distress syndrome |
| JP3117192B2 (ja) | 1996-04-09 | 2000-12-11 | 有限会社ホワイト | 酸化還元電位測定機能内蔵健康管理計 |
| SE9603569D0 (sv) * | 1996-09-30 | 1996-09-30 | Pacesetter Ab | Electrochemical sensor |
| US6269261B1 (en) * | 1996-10-26 | 2001-07-31 | Yugen Kaisha Endo Process | Health care instrument containing oxidation-reduction potential measuring function |
| US6369106B1 (en) * | 1996-12-26 | 2002-04-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Treatment of ischemic brain injuries with brain targeted anti oxidant compounds |
| AU6157898A (en) * | 1997-02-06 | 1998-08-26 | E. Heller & Company | Small volume (in vitro) analyte sensor |
| EP0966719A1 (en) | 1997-03-13 | 1999-12-29 | Opinion Corporation First | Disease management system |
| US6177260B1 (en) * | 1997-07-11 | 2001-01-23 | The Hong Kong Polytechnic University | Measurement of antioxidant (reducing) power and/or antioxidant concentration |
| JPH1183797A (ja) * | 1997-09-03 | 1999-03-26 | Yoshitaka Otomo | 生物用酸化還元電位測定装置 |
| US5906921A (en) * | 1997-09-29 | 1999-05-25 | Matsushita Electric Industrial Co., Ltd. | Biosensor and method for quantitative measurement of a substrate using the same |
| SE9703958D0 (sv) * | 1997-10-29 | 1997-10-29 | Pacesetter Ab | Method and device for determination of concentration |
| SE9703957D0 (sv) * | 1997-10-29 | 1997-10-29 | Pacesetter Ab | Method and device for sensing |
| US6429021B1 (en) * | 1998-03-19 | 2002-08-06 | Amway Corporation | Antioxidant activity profile assay |
| DE69937326T2 (de) * | 1998-04-02 | 2008-07-17 | Matsushita Electric Industrial Co., Ltd., Kadoma | Verfahren zur bestimmung eines substrates |
| AU4215999A (en) * | 1998-06-01 | 1999-12-20 | Roche Diagnostics Corporation | Redox reversible imidazole-osmium complex conjugates |
| DK1083824T3 (da) * | 1998-06-04 | 2009-07-13 | Sphere Medical Ltd | Kalibreringsvæske til en sensor til måling af en blodværdi samt fremstilling af kalibreringsvæsken |
| JP3267936B2 (ja) * | 1998-08-26 | 2002-03-25 | 松下電器産業株式会社 | バイオセンサ |
| DE19846148C2 (de) * | 1998-10-01 | 2002-10-10 | Igor Popov | Verfahren zur Beurteilung der oxidativen Modifikation proteinhaltiger Stoffe mittels Messung ihrer antiradikalen Aktivität |
| US20050142613A1 (en) * | 1998-10-02 | 2005-06-30 | David Bar-Or | Test for the rapid evaluation of ischemic states and kits |
| JP4205792B2 (ja) * | 1998-12-04 | 2009-01-07 | 日本碍子株式会社 | ＮＯｘ分解電極及びＮＯｘ濃度測定装置 |
| CA2378678C (en) * | 1999-06-08 | 2009-08-04 | Broadley Technologies Corporation | Reference electrode having a microfluidic flowing liquid junction |
| US6616819B1 (en) * | 1999-11-04 | 2003-09-09 | Therasense, Inc. | Small volume in vitro analyte sensor and methods |
| WO2002028348A2 (en) * | 2000-10-04 | 2002-04-11 | The Children's Hospital Of Philadelphia | Compositions and methods for treatment of cystic fibrosis |
| JP4154884B2 (ja) | 2000-11-10 | 2008-09-24 | 慶孝 大友 | 酸化還元電位測定装置および方法 |
| US7015310B2 (en) | 2001-03-12 | 2006-03-21 | The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon | Oxidation reduction sensitive green fluorescent protein variants |
| US6793632B2 (en) * | 2001-06-12 | 2004-09-21 | Lifescan, Inc. | Percutaneous biological fluid constituent sampling and measurement devices and methods |
| FR2829579A1 (fr) | 2001-09-11 | 2003-03-14 | Endogenics | Procede pour evaluer l'etat biologique d'un patient |
| GB0124613D0 (en) * | 2001-10-12 | 2001-12-05 | Alpha Thames Ltd | System and method for separating fluids |
| US7063782B2 (en) * | 2001-11-26 | 2006-06-20 | Ischemia Technologies, Inc. | Electrochemical detection of ischemia |
| US7132296B2 (en) | 2002-02-15 | 2006-11-07 | Medical Products Manufacturing, Llc | Method for assaying the antioxidant capacity of a sample |
| AU2002951886A0 (en) | 2002-10-08 | 2002-10-24 | The Western Australian Centre For Pathology And Medical Research | A method for measuring antioxident status |
| AU2003287735A1 (en) * | 2002-11-12 | 2004-06-03 | Argose, Inc. | Non-invasive measurement of analytes |
| GR1004535B (el) | 2003-01-27 | 2004-04-22 | Medicon Hellas A.E. | Αυτοματοποιημενη μεθοδος προσδιορισμου της ολικης αντιοξειδωτικης ικανοτητος (total antioxidant capacity -tac-), και της διορθωμενης ολικης αντιοξειδωτικης ικανοτητος (corr tac) σε βιολογικα υγρα καιεκχυλισματα τροφων και ποτων βασισμενη στην αναστολη οξειδωσεως της κροκινης |
| JP2004350861A (ja) * | 2003-05-28 | 2004-12-16 | Tanita Corp | 健康管理装置 |
| US7276382B2 (en) | 2003-10-02 | 2007-10-02 | Noboru Horiguchi | Blood testing method |
| US20050139469A1 (en) * | 2003-10-31 | 2005-06-30 | Davies Oliver W.H. | Electrochemical test strip for reducing the effect of direct and mediated interference current |
| RU2241997C1 (ru) | 2003-11-18 | 2004-12-10 | Евсеев Максим Александрович | Способ определения окислительно-восстановительного потенциала стенки желудка и двенадцатиперстной кишки |
| EP1778592B1 (en) | 2004-07-07 | 2013-07-31 | Disney Enterprises, Inc. | Process control oxidation |
| GR1005561B (el) | 2005-10-03 | 2007-06-15 | Γεωργιος Κολιακος | Μετρηση της ολικης αντιοξειδωτικης ικανοτητος σε υγρα και διαλυμματα με τη χρηση της 3,3',5,5'-τετραμεθυλοβενζιδινης (τμβ) |
| WO2007059455A2 (en) | 2005-11-10 | 2007-05-24 | Virginia Commonwealth University | Non-biofouling, universal redox electrode and measurement system |
| EP1790356A1 (de) | 2005-11-24 | 2007-05-30 | Vifor (International) Ag | Präparat, umfassend Eisen(III)-Komplexverbindungen und redoxaktive Substanz(en) |
| EP1906178A1 (en) * | 2006-09-26 | 2008-04-02 | F.Hoffmann-La Roche Ag | Method for detecting erroneous measurement results obtained with ion-selective electrodes |
| JP5330381B2 (ja) | 2007-05-18 | 2013-10-30 | インスティチュート フォー モレキュラー メディスン インコーポレイテッド | 酸化還元電位（ｏｒｐ）を測定及び使用する方法 |
| US8709709B2 (en) | 2007-05-18 | 2014-04-29 | Luoxis Diagnostics, Inc. | Measurement and uses of oxidative status |
| CA2817163C (en) | 2011-02-28 | 2015-02-17 | Luoxis Diagnostics, Inc. | Method and apparatus for measuring oxidation-reduction potential |
| AU2013334616A1 (en) | 2012-10-23 | 2014-06-26 | Aytu Bioscience, Inc. | Methods and systems for measuring and using the oxidation-reduction potential of a biological sample |
-
2008
- 2008-05-16 JP JP2010509472A patent/JP5330381B2/ja not_active Expired - Fee Related
- 2008-05-16 CA CA2684144A patent/CA2684144C/en active Active
- 2008-05-16 EP EP08755661.9A patent/EP2147303B1/en active Active
- 2008-05-16 US US12/121,945 patent/US9063070B2/en active Active
- 2008-05-16 ES ES08755661.9T patent/ES2627188T3/es active Active
- 2008-05-16 CA CA2931413A patent/CA2931413A1/en not_active Abandoned
- 2008-05-16 WO PCT/US2008/063855 patent/WO2008144481A1/en not_active Ceased
-
2013
- 2013-06-05 JP JP2013118787A patent/JP2013178277A/ja active Pending
- 2013-09-03 US US14/016,889 patent/US9383331B2/en active Active
-
2014
- 2014-02-27 JP JP2014036847A patent/JP2014134545A/ja active Pending
-
2016
- 2016-03-17 JP JP2016053891A patent/JP2016118568A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013178277A (ja) | 2013-09-09 |
| US20140004551A1 (en) | 2014-01-02 |
| WO2008144481A1 (en) | 2008-11-27 |
| EP2147303B1 (en) | 2017-03-29 |
| JP2016118568A (ja) | 2016-06-30 |
| JP2010528290A (ja) | 2010-08-19 |
| ES2627188T3 (es) | 2017-07-27 |
| US9063070B2 (en) | 2015-06-23 |
| US9383331B2 (en) | 2016-07-05 |
| CA2931413A1 (en) | 2008-11-27 |
| EP2147303A1 (en) | 2010-01-27 |
| CA2684144A1 (en) | 2008-11-27 |
| EP2147303A4 (en) | 2010-09-01 |
| CA2684144C (en) | 2018-03-27 |
| US20090004686A1 (en) | 2009-01-01 |
| JP2014134545A (ja) | 2014-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016118568A (ja) | 酸化状態の測定及び使用方法 | |
| US10036723B2 (en) | Measurement and uses of oxidative status | |
| Banne et al. | Reduced level of serum thiols in patients with a diagnosis of active disease | |
| EP2466312B1 (en) | Phosphoethanolamine as biomarker of depression | |
| Grigorieva et al. | Measurement of plasma hemoglobin peroxidase activity | |
| ES2549860T3 (es) | Diagnóstico y pronóstico de estados patológicos relacionados con la dipepitidil peptidasa | |
| González-Quevedo et al. | Increased serum S-100B and neuron specific enolase—Potential markers of early nervous system involvement in essential hypertension | |
| Miró et al. | Skeletal muscle mitochondrial function is preserved in young patients with chronic renal failure | |
| Muzembo et al. | A cross-sectional assessment of oxidative DNA damage and muscle strength among elderly people living in the community | |
| Son et al. | Cerebrospinal fluid lactate levels, brain lactate metabolism and neurologic outcome in patients with out-of-hospital cardiac arrest | |
| EP4549941A1 (en) | Colorectal cancer biomarker and use thereof | |
| TWI735470B (zh) | 糖尿病性腎病之判定方法、及於此種判定方法中生物標記之用途 | |
| EP3363347A1 (en) | Method for the early detection of acute kidney injury in critical patients, using fibroblast growth factor 23, klotho and erythropoietin as biomarkers | |
| SG185004A1 (en) | Immune and oxygen system measuring and drug screening method and apparatus | |
| RU2680848C1 (ru) | Способ оценки характера аутоиммунной реакции организма человека на множественно модифицированные липопротеины низкой плотности в литическом тесте | |
| JP5208028B2 (ja) | Ｅｄ評価方法 | |
| Ito et al. | Blood oxidative stress levels and urinary dopamine values reflect the impact of academic stress on students | |
| Wang | Lifestyle intervention in women with obesity and infertility: metabolic and nutritional characteristics and reproductive outcomes | |
| RU2327991C2 (ru) | Способ ранней диагностики прогрессирования идиопатического сколиоза | |
| Masarogullari et al. | Urinary GGT: A cheaper predictor of acute kidney injury? | |
| HK40104551A (en) | Physical frailty testing method, physical frailty testing reagent, screening method for physical frailty therapeutic drug candidate substance, mental frailty testing method, mental frailty testing reagent, and screening method for mental frailty therapeutic drug candidate substance | |
| Bhoi Bharat et al. | Comparison of estimated glomerular filtration rate using different analytes in chronic kidney disease patients | |
| Lee et al. | Altered electrolyte and creatinine measurement with add-on testing on vitros 5600 and 5, 1 systems when using micro-container cups with pierceable caps | |
| JP2021076410A (ja) | 肺がん罹患のリスクを評価するための方法 | |
| Kaski | International Journal of Medical and Health Sciences |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110513 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20120123 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120508 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120731 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121029 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121105 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130131 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130305 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130605 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130702 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130725 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5330381 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| S631 | Written request for registration of reclamation of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313631 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |